---
url: https://www.servicesaustralia.gov.au/systemic-lupus-erythematosus
title: Systemic lupus erythematosus - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:54.683Z
source: servicesaustralia.gov.au
---
# Systemic lupus erythematosus

The PBS subsidises anifrolumab for patients with systemic lupus erythematosus (SLE).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Toxicity and severity descriptors](#a3)
-   [Treatment specifics](#a4)
-   [Authority applications](#a5)
-   [More information](#a6)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with anifrolumab under the _National Health Act 1953_, section 100 for patients with SLE.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing anifrolumab.

## Section 100 arrangements

### anifrolumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

-   an approved private hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Toxicity and severity descriptors

When demonstrating a patient’s intolerance to prior treatment, use the [systemic lupus erythematosus toxicity and severity descriptors](/systemic-lupus-erythematosus-toxicity-and-severity-descriptors?context=20) with the authority application.

## Treatment specifics

To be eligible for PBS-subsidised treatment with anifrolumab, patients must be treated by a specialist physician experienced in the management of SLE.

## Authority applications

### Applying for initial treatment

Apply for initial authority approval to prescribe PBS-subsidised anifrolumab to treat SLE in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [systemic lupus erythematosus - anifrolumab - initial authority application form](/pb365?context=20)
-   relevant attachments.

### Applying for continuing or recommencement of treatment

Applications to continue or recommence authority approval to prescribe PBS-subsidised anifrolumab to treat SLE can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.

[

Systemic lupus erythematosus toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat systemic lupus erythematosus.


](/systemic-lupus-erythematosus-toxicity-and-severity-descriptors?context=20)
